The Future of Hybrid Healthcare | Chuck Piccirillo
BioTalk Unzipped15 Aug 2024

The Future of Hybrid Healthcare | Chuck Piccirillo

Patients increasingly expect healthcare to work the way the rest of their lives work: flexibly, digitally, and around their individual needs.

Chuck Piccirillo returns to BioTalk Unzipped to explore how healthcare organizations can build more adaptive patient journeys without losing the human connection that remains essential to care.

Chuck explains why different patients, therapies, and diseases require different engagement models and why digital health platforms need to be adaptable rather than static.

The conversation examines the growing demand for hybrid healthcare, combining virtual and in-person interactions, and the emergence of virtual-health models in Europe.

In New News, the group explores ion channels and why these microscopic cellular structures continue attracting significant interest as targets for new medicines.

From there, Gregory, Chad, and Chuck move into the economics of drug development and the realities of building a life-sciences company.

Chuck offers lessons on leadership, persistence, incremental progress, and why face-to-face human interaction still matters even in increasingly digital organizations.

The episode concludes with practical advice for entrepreneurs trying to build businesses in life sciences, where scientific ambition has to coexist with capital constraints, regulatory requirements, execution, and patience.

Chapters

00:17 - Adapting to what is unique about each patient journey

07:08 - The push toward hybrid healthcare and greater flexibility

09:20 - The emergence of virtual health, particularly in Europe

14:02 - New News: Why ion channels are a goldmine for new medicines

19:23 - The financial side of drug development

21:50 - Leadership, incremental progress, in-person interaction, and hard lessons

30:58 - Advice for entrepreneurs in life sciences

Key ideas
  • Digital patient experiences should adapt to the patient and therapy rather than forcing every patient into the same process.
  • Hybrid healthcare can combine the convenience of technology with necessary in-person care.
  • Remote monitoring and virtual interactions may reduce some burdens on patients and healthcare providers.
  • Ion channels continue to represent an important area of therapeutic research.
  • Persistence and incremental progress are fundamental to entrepreneurship.
  • Technology does not eliminate the value of real human relationships.

Crohn’s & Colitis Foundation

https://www.crohnscolitisfoundation.org/

Connect with Chuck Piccirillo

Chuck Piccirillo

https://www.linkedin.com/in/cpiccirillo/

Zealic Health

http://www.zealichealth.com

Connect with the hosts

Dr. Chad Briscoe

https://www.linkedin.com/in/chadbriscoe/

Gregory Austin

https://www.linkedin.com/in/gregoryaustin1/

New News

These microscopic tunnels are a goldmine for new medicines:

https://www.biopharmadive.com/news/ion-channels-drug-research-vertex-biohaven-jazz/719337/

Keywords

patient journey, hybrid healthcare, virtual health, ion channels, drug development, life sciences entrepreneurship, remote patient monitoring, decentralized clinical trials, digital health, leadership

#HealthcareInnovation #VirtualHealth #DrugDevelopment #LifeSciences #DigitalHealth #IonChannels #ClinicalTrials #Leadership #Biotechnology

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(45)

Why Gene Therapy Is Still So Hard to Manufacture at Scale | Phillip Ramsey

Why Gene Therapy Is Still So Hard to Manufacture at Scale | Phillip Ramsey

Why is gene therapy still so difficult to manufacture at scale after decades of progress?Phillip Ramsey, Chief Technical Officer at Sangamo Therapeutics, joins BioTalk Unzipped for a candid conversati...

8 Aug 11min

Her Daughter’s Brain Tumor Turned Her Into a Biotech Founder | Tracy Ryan

Her Daughter’s Brain Tumor Turned Her Into a Biotech Founder | Tracy Ryan

A mother’s search for answers to her daughter’s relentless brain tumor led her into natural killer cell biology, cancer immunotherapy, and biotech entrepreneurship.Sponsored by Leucentra, https://leuc...

20 Jul 1h 4min

The Future of Oncology Drug Development | Dr. Lakshmi Amaravadi

The Future of Oncology Drug Development | Dr. Lakshmi Amaravadi

Oncology drug development is becoming more complex, and bioanalysis can no longer be treated as simple drug measurement.Sponsored by Leucentra, https://leucentra.com/Inspired by science, empowered by ...

11 Jun 29min

Active Machine Learning for Drug Discovery & Nanomedicine with Dr. Daniel Reker

Active Machine Learning for Drug Discovery & Nanomedicine with Dr. Daniel Reker

Can artificial intelligence help make cancer therapies safer, more targeted, and more effective?In this episode of BioTalk Unzipped, Gregory Austin sits down with Dr. Daniel Reker, Assistant Professor...

25 Apr 50min

Why Haven’t We Cured Cancer Yet? | Dr. Bob Liu Explains

Why Haven’t We Cured Cancer Yet? | Dr. Bob Liu Explains

Why haven’t we cured cancer yet? A Genentech scientist explains the real reason.In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Bob Liu, Senior Principal Sci...

19 Mar 1h

The Intersection of Biotech, Patent Law, and AI with Dr. Kate Neville, IP Attorney

The Intersection of Biotech, Patent Law, and AI with Dr. Kate Neville, IP Attorney

Recorded October 31, 2025In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Kate Neville, immunologist turned seasoned biotech patent attorney at Marshall, Gers...

16 Feb 52min

Long-acting Cell-Based Gene Therapy, Fabry Disease and Beyond with Glafabra CEO, Dr. Chris Hopkins

Long-acting Cell-Based Gene Therapy, Fabry Disease and Beyond with Glafabra CEO, Dr. Chris Hopkins

In this episode of BioTalk Unzipped, hosts Gregory Austin and Dr. Chad Briscoe sit down with Glafabra CEO: Dr. Chris Hopkins, geneticist, biochemist, and biotech entrepreneur, to explore the science a...

22 Des 202549min

Fail Fast, Learn Faster: Drug Development in Rare Disease with Dr. Binodh DeSilva

Fail Fast, Learn Faster: Drug Development in Rare Disease with Dr. Binodh DeSilva

In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Binodh DeSilva, Senior Vice President of Bioanalysis at Ultragenyx Pharmaceutical, to explore the science and...

23 Okt 202531min

Populært innen Business og økonomi

stopp-verden
lydartikler-fra-aftenposten
dine-penger-pengeradet
rss-penger-polser-og-politikk
e24-podden
rss-borsmorgen-okonominyhetene
rss-skravla-gar
lederpodden
rss-pa-konto
utbytte
pengepodden-2
livet-pa-veien-med-jan-erik-larssen
morgenkaffen-med-finansavisen
finansredaksjonen
tid-er-penger-en-podcast-med-peter-warren
liberal-halvtime
rss-markedspuls-2
pengesnakk
rss-politisk-preik
okonomiamatorene